Proprotein convertase inhibition: Paralyzing the cell's master switches

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Proprotein convertases (PCs) are serine proteases crucial for activating protein substrates.
• Dysregulation of PC activity is implicated in various diseases, including cancer, endocrinopathies, cardiovascular, and infectious diseases.
• Specific PCs like furin, PACE4, and PCSK-9 have distinct substrate recognition and roles in pathology.

Purpose of the Study:

• To review the role of proprotein convertases in disease pathogenesis.
• To summarize the development and efficacy of various PC inhibition strategies.
• To highlight current clinical trial progress and future directions in PC-targeted therapies.

Main Methods:

• Review of existing literature on proprotein convertases and their inhibitors.
• Analysis of pre-clinical and clinical trial data for PC-targeted therapies.
• Identification of specific PC activities and their therapeutic potential.

Main Results:

• PC-mediated substrate activation contributes to diseases like cancer and cardiovascular conditions.
• Inhibitors, including small molecules, antibodies, and bioengineered proteins, are effective in blocking PC activity.
• Clinical trials show efficacy for PACE4 inhibitors in prostate cancer, furin inhibitors in ovarian cancer, and PCSK-9 antibodies in lowering HDL-cholesterol.

Conclusions:

• Proprotein convertase research has matured, with inhibitors demonstrating significant therapeutic potential.
• Targeting specific PCs offers promising avenues for experimental pharmacology and disease treatment.
• Future challenges include developing allosteric inhibitors and agents specific to individual PCs.